期刊文献+

PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应 被引量:7

Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lew is lung cancer mice
原文传递
导出
摘要 目的探讨程序性死亡受体-1(PD-1)单克隆抗体联合血管内皮抑素对Lewis肺癌小鼠的抗肿瘤效应。方法构建Lewis肺癌C57BL/6小鼠移植瘤模型,随机分为4个组:PBS对照组(A组)、PD-1单克隆抗体组(B组)、血管内皮抑素组(C组)、PD-1单克隆抗体联合血管内皮抑素组(D组)。测量小鼠肺内肿瘤体积,ELISA检测小鼠血浆中INFγ的含量,免疫组织化学染色检测肿瘤组织的CD31和VEGF。结果与A组相比,B组、D组肿瘤生长受到明显抑制(P均<0.001),C组肿瘤虽有缩小但差异无统计学意义(P=0.084);与A组相比,B、C、D组血浆中INFγ的浓度明显升高(P均<0.001),D组升高最为明显;与A组相比,D组小鼠肿瘤组织中VEGF的阳性表达最低(P<0.001);MVD计数D组降低,与A组相比(P<0.001),D组与B组相比(P=0.019),D组与C组相比(P<0.001)。结论 PD-1单克隆抗体联合血管内皮抑素治疗明显减缓肿瘤生长速度,有效改善肿瘤微环境,有明显协同抗肿瘤作用。 Objective To explore the antitumor effect of anti-PD-1 combined with angioendostatin on lung cancer in Lewis mice. Methods Lewis lung cancer C57 BL/6 mice models were constructed and randomly divided into 4 groups: group A( PBS control),group B( anti-PD-1),group C( endostatin) and group D( anti-PD-1 combined with endostatin). The tumor volume was measured. The content of INFγ in the plasma was detected with ELISA,and the CD31 and VEGF contents were determined with immunohistochemistry. Results Compared with group A,group B and D had significantly inhibited tumor growth( P〈0. 001); group Chad reduced tumor size but there was no statistical difference( P = 0. 084). Compared with group A,groups D,C and B had significantly elevated INFγ concentration(P〈0. 001),and group D showed the most obvious increase. Compared with group A,group D had significantly lower positive expression of VEGF( P〈0. 001). MVD count decreased significantly in group D compared with that in group A( P〈0. 001),group D compared with group B( P = 0. 019),and group D compared with group C( P〈0.001). Conclusion Anti-PD-1 combined with endostatin can significantly slowdown the tumor growth,effectively improve the tumor microenvironment,and play a synergistic antitumor effect.
作者 姜运峰 董晓鹏 赵小刚 JIANG Yunfeng;DONG Xiaopeng;ZHAO Xiaogang(Department of Thoracic Surgery,the Second Hospital of Shandong University,Jinan 250033,Shandong,China)
出处 《山东大学学报(医学版)》 CAS 北大核心 2018年第9期11-16,共6页 Journal of Shandong University:Health Sciences
基金 山东省自然科学基金面上项目(ZR2015HM054) 山东省重点研发计划(重大关键技术)(2016ZDJS07A15)
关键词 肺肿瘤 程序性死亡受体-1 血管内皮抑素 肿瘤微环境 Lung cancer Programmed cell death-1 Endostatin Tumor microenvironrnent
  • 相关文献

参考文献2

二级参考文献45

  • 1Siegel RL, Miller KD,JemaI A Cancer statistics, 2016. CA CancerJ elin 2016;66:7-30.
  • 2Sharma P, Wagner K, WolchokJD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-12.
  • 3McNutt M. Cancer immunotherapy. Science 2013;342: 1417.
  • 4Rosenberg SA Overcoming obstacles to the effective immunotherapy of human cancer. Proc Nad Acad Sci USA 2008;105:12643-4.
  • 5Pao W New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc 2012;9:72-3.
  • 6Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 20 14;26:204-14.
  • 7Romagnoli GG, Zelante BB, Toniolo PA, et al. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front Immuno12015;5:692.
  • 8Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Ann NY Acad Sci 2013;1284:31-45.
  • 9H Yi D, Appel S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand J Immunol 2013;78:167-71.
  • 10Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.

共引文献16

同被引文献70

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部